FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Cancer
Naveen PemmarajuJorge Cortes

Abstract

Despite recent modest improvements in the chemotherapy regimens used to treat acute myeloid leukemia (AML), many patients diagnosed with AML ultimately die of the disease. Commonly occurring genetic alterations have been identified that strongly affect the prognosis for patients with AML. These alterations represent possible targets for investigational therapies that could act to specifically halt the aberrant growth of AML cells while limiting damage to normal cells. One such gene is the Fms-like tyrosine kinase 3 (FLT3) gene, which is mutated in approximately 30% of adult patients with AML and has a significant impact on prognosis. In particular, internal tandem duplications in FLT3 confer a poor prognosis to this large subgroup of patients with AML. Agents that target FLT3 are in development for the treatment of patients who have AML and offer a potential paradigm change in the current standard treatment of AML. For this report, the authors reviewed the prognostic significance of genetic alterations observed in AML with a focus on the therapeutic implications of targeting FLT3. The introduction of such agents may be the next major step toward the era of personalized therapy in AML.

References

Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J PropperC Twelves
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingUNKNOWN Acute Myeloid Leukemia Study Group, Ulm
Aug 27, 2002·Annual Review of Genomics and Human Genetics·Louise M Kelly, D Gary Gilliland
Jan 11, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Birgit KainzUlrich Jaeger
Feb 8, 2003·Current Opinion in Genetics & Development·James R Downing
Apr 15, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Sahar Barjesteh van Waalwijk van Doorn-KhosrovaniRuud Delwel
Aug 22, 2003·The New England Journal of Medicine·Charles A Schiffer
Sep 3, 2003·Nature Reviews. Cancer·Derek L Stirewalt, Jerald P Radich
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marianne BienzThomas Pabst
Nov 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia D BaldusGerhard Ehninger
Jun 8, 2006·International Journal of Hematology·Hitoshi Kiyoi, Tomoki Naoe
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich

❮ Previous
Next ❯

Citations

Oct 19, 2012·Nature Reviews. Cancer·Kenneth Verstraete, Savvas N Savvides
Jul 28, 2013·Leukemia & Lymphoma·Aziz Nazha, Farhad Ravandi
Apr 23, 2014·Expert Opinion on Investigational Drugs·Naveen PemmarajuFarhad Ravandi
Mar 21, 2016·Bioorganic & Medicinal Chemistry Letters·Hirofumi NakanoTetsuo Nagano
Jan 30, 2015·Clinical Lymphoma, Myeloma & Leukemia·Syed M KazmiJorge Cortes
Oct 31, 2012·Bioorganic & Medicinal Chemistry Letters·Ghislaine Marlyse Okala AmomboBoris Schmidt
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Jun 15, 2017·Future Oncology·Mrinal M Patnaik
Nov 18, 2017·The Oncologist·Manuela Schmidinger, Romano Danesi
Dec 5, 2012·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Tomoki Naoe
Aug 11, 2020·Expert Opinion on Pharmacotherapy·Alejandro Garcia-Horton, Karen Wl Yee
Apr 2, 2019·Frontiers in Immunology·Michael S Heath, Alex G Ortega-Loayza

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.